Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Däumer

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 29, 2006
Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAARTClara Lehmann, Martin Däumer, Ibrahim Boussaad, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2010
Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolatesElena Knops, Martin Däumer, Sabine Awerkiew, et al.
Open Forum Infectious Diseases|September 17, 2024
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class ResistanceJacob Gerstenberg, Hartwig Klinker, Michael Baier, et al.
The Journal of Antimicrobial Chemotherapy|May 19, 2009
Evolution of raltegravir resistance during therapyNadine Sichtig, Saleta Sierra, Rolf Kaiser, et al.
Cell Reports Methods|July 10, 2023
Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periodsFabian Otte, Yuepeng Zhang, Julian Spagnuolo, et al.
Antiviral Research|November 21, 2012
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078Simon Portsmouth, Srinivas Rao Valluri, Martin Däumer, et al.
AIDS Research and Therapy|February 15, 2011
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?Frank Wiesmann, Jan Vachta, Robert Ehret, et al.
Tropical Medicine & International Health : TM & IH|January 28, 2020
High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from TanzaniaArne Kroidl, Tassilo Burger, Agatha Urio, et al.
Antiviral Therapy|February 17, 2007
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patientsJens Verheyen, Elena Litau, Tobias Sing, et al.
Antiviral Therapy|September 14, 2010
Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolatesJens Verheyen, Finja Schweitzer, Ellen G Harrer, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 29, 2006
Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAARTClara Lehmann, Martin Däumer, Ibrahim Boussaad, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2010
Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolatesElena Knops, Martin Däumer, Sabine Awerkiew, et al.
Open Forum Infectious Diseases|September 17, 2024
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class ResistanceJacob Gerstenberg, Hartwig Klinker, Michael Baier, et al.
The Journal of Antimicrobial Chemotherapy|May 19, 2009
Evolution of raltegravir resistance during therapyNadine Sichtig, Saleta Sierra, Rolf Kaiser, et al.
Cell Reports Methods|July 10, 2023
Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periodsFabian Otte, Yuepeng Zhang, Julian Spagnuolo, et al.
Antiviral Research|November 21, 2012
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078Simon Portsmouth, Srinivas Rao Valluri, Martin Däumer, et al.
AIDS Research and Therapy|February 15, 2011
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?Frank Wiesmann, Jan Vachta, Robert Ehret, et al.
Tropical Medicine & International Health : TM & IH|January 28, 2020
High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from TanzaniaArne Kroidl, Tassilo Burger, Agatha Urio, et al.
Antiviral Therapy|February 17, 2007
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patientsJens Verheyen, Elena Litau, Tobias Sing, et al.
Antiviral Therapy|September 14, 2010
Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolatesJens Verheyen, Finja Schweitzer, Ellen G Harrer, et al.
Pageof 6